Nathaniel Gardiner Email

SVP and General Counsel . Enanta Pharmaceuticals

Current Roles

Employees:
196
Revenue:
$39.4M
About
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved around the world as part of AbbVie's regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.
Enanta Pharmaceuticals Address
500 Arsenal Street
Watertown, MA
United States
Enanta Pharmaceuticals Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.